PAHC

Phibro Animal Health Corp. (PAHC) - Q1 2026 (Ended Sept 30, 2025) Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2025. Phibro Animal Health Corporation is a global developer and manufacturer of animal health, mineral nutrition, and performance products. The reporting period reflects the full impact of the October 2024 acquisition of the medicated feed additives portfolio from Zoetis, which significantly expanded the Animal Health segment.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased by $103.5 million, driven primarily by the Animal Health segment (+55%). This includes $80.5 million in revenue from the Zoetis acquisition, alongside organic growth in North and South America.
• Profitability: Operating income surged to $51.3 million from $17.7 million, aided by favorable product mix, higher average selling prices, and the acquired portfolio's contribution.
• Interest Expense: Net interest expense rose 58% to $12.1 million due to higher debt levels financing the acquisition and the expiration of a favorable interest rate swap.
• Foreign Currency: Net foreign currency losses increased to $2.9 million (from $0.4 million), largely due to fluctuations in the Argentine Peso and Israeli New Shekel.
• Segment Performance:
  • Animal Health: Sales $283.5M; Adjusted EBITDA $74.9M.
  • Mineral Nutrition: Sales $63.0M; Adjusted EBITDA $4.5M.
  • Performance Products: Sales $17.4M (down 7%); Adjusted EBITDA $1.6M.

Outlook, Risks, and Unusual Items

• Acquisition Integration: The Zoetis acquisition is fully integrated into results. Management notes that purchase accounting adjustments (step-up in inventory and PP&E) impacted cost of goods sold by $1.1 million in the quarter.
• Geopolitical Risks:
  • Israel: Operations in Israel (16% of assets, 17% of sales) face risks from ongoing conflict with Hamas and Hezbollah. Management states operations are currently meeting supply commitments but acknowledges potential for disruption.
  • Russia/Ukraine: Sales to the region represent ~1% of consolidated net sales. Risks include sanctions and supply chain volatility.
• Regulatory Risks: The FDA is proceeding with a process to withdraw approval of the regulatory method for carbadox (Mecadox). Phibro is defending the product, which generated ~$22 million in sales over the last 12 months. Loss of this product would adversely affect results.
• Unusual Items:
  • Insurance Proceeds: $3.8 million in insurance proceeds were recorded in SG&A, partially offsetting expenses.
  • Acquisition Costs: $0.3 million in transaction costs were incurred in the current quarter compared to $3.4 million in the prior year.
• Dividends: The Board declared a quarterly dividend of $0.12 per share, payable December 17, 2025.

Investor Verification Checklist

• Acquisition Synergies: Verify the timeline for realizing cost synergies and revenue enhancements from the Zoetis portfolio beyond the initial revenue contribution.
• Israel Operations: Monitor the stability of the ceasefire and potential for escalation that could disrupt the 17% of sales generated from Israeli facilities.
• Carbadox (Mecadox) Status: Track the FDA administrative hearing process regarding the regulatory method for carbadox, as a loss of approval would impact the Animal Health segment.
• Debt Covenants: Confirm continued compliance with the 2024 Credit Agreement covenants, specifically the Net Leverage Ratio (currently compliant) and Interest Coverage Ratio.
• Foreign Exchange Exposure: Assess the impact of continued volatility in the Argentine Peso and Israeli New Shekel on future earnings.